Novel hits for autosomal dominated polycystic kidney disease (ADPKD) targeting derived by in silico screening on ZINC-15 natural product database

References

• Abraham, M., van der Spoel, D., Lindahl, E., & Hess, B., The G. Development Team. (2019). Gromacs 2019.2. GROMACS user man version 19. https://manual.gromacs.org/
   Google Scholar
• Berendsen, H. J., Jv, P., Van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684–3690.
   Web of Science ®Google Scholar
• Blair, H. A. (2019). Tolvaptan: A review in autosomal dominant polycystic kidney disease. Drugs, 79(3), 303–313.
   PubMed Web of Science ®Google Scholar
• Brill, A. L., & Ehrlich, B. E. (2020). Polycystin 2: A calcium channel, channel partner, and regulator of calcium homeostasis in ADPKD. Cellular Signalling, 66, 109490.
   PubMed Web of Science ®Google Scholar
• Brogi, S., Ramalho, T. C., Kuca, K., Medina-Franco, J. L., & Valko, M. (2020). In silico methods for drug design and discovery (p. 612). Frontiers Media SA.
   Google Scholar
• Bussi, G., Donadio, D., & Parrinello, M. (2007). Canonical sampling through velocity rescaling. The Journal of Chemical Physics, 126(1), 014101.
   PubMed Web of Science ®Google Scholar
• Cadnapaphornchai, M. A. (2017). Clinical trials in pediatric autosomal dominant polycystic kidney disease. Frontiers in Pediatrics, 5, 53.
   PubMed Web of Science ®Google Scholar
• Chebib, F. T., Perrone, R. D., Chapman, A. B., Dahl, N. K., Harris, P. C., Mrug, M., Mustafa, R. A., Rastogi, A., Watnick, T., Yu, A. S. L., & Torres, V. E. (2018). A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. Journal of the American Society of Nephrology: JASN, 29(10), 2458–2470. https://doi.org/10.1681/ASN.2018060590
   PubMed Web of Science ®Google Scholar
• Chebib, F. T., Sussman, C. R., Wang, X., Harris, P. C., & Torres, V. E. (2015). Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nature Reviews. Nephrology, 11(8), 451–464. https://doi.org/10.1038/nrneph.2015.39
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092.
   Web of Science ®Google Scholar
• Eroglu, E., Kocyigit, I., Taheri, S., Zararsiz, G., Sener, E., Uzun, I., Imamoglu, H., Mehmetbeyoglu, E., Unal, A., & Korkmaz, K. (2018). The association of osr-1 between vascular dysfunction and hypertension in polycystic kidney disease. Nephrology Dialysis Transplantation, 33.
   Web of Science ®Google Scholar
• Gao, J., Zhou, H., Lei, T., Zhou, L., Li, W., Li, X., & Yang, B. (2011). Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. European Journal of Pharmacology, 654(1), 92–99.
   PubMed Web of Science ®Google Scholar
• He, W.-B., Xiao, W.-J., Tan, Y.-Q., Zhao, X.-M., Li, W., Zhang, Q.-J., Zhong, C.-G., Li, X.-R., Hu, L., & Lu, G.-X. (2018). Novel mutations of PKD genes in Chinese patients suffering from autosomal dominant polycystic kidney disease and seeking assisted reproduction. BMC Medical Genetics, 19(1), 1–13.
   PubMedGoogle Scholar
• Helal, I. (2013). Autosomal dominant polycystic kidney disease: New insights into treatment. Saudi Journal of Kidney Diseases and Transplantation, 24(2), 230–234. https://doi.org/10.4103/1319-2442.109561
   PubMedGoogle Scholar
• Hess, B., Bekker, H., Berendsen, H. J., & Fraaije, J. G. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472.
   Web of Science ®Google Scholar
• Igarashi, P., & Somlo, S. (2002). Genetics and pathogenesis of polycystic kidney disease. Journal of the American Society of Nephrology: JASN, 13(9), 2384–2398. https://doi.org/10.1097/01.asn.0000028643.17901.42
   PubMed Web of Science ®Google Scholar
• Iranshahy, M., & Iranshahi, M. (2011). Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin)—A review. Fitoterapia, 134(1), 1–10.
   Google Scholar
• Jahani, M., Akaberi, M., Heidari, T., Kamali, H., Nejabat, M., Rajabi, O., & Hadizadeh, F. J. (2023). Simultaneous determination of mometasone furoate and calcipotriol in a binary mixture by validated HPLC and chemometric-assisted UV spectrophotometric methods and identification of degradation products by LC-MS. Iranian Journal of Basic Medical Sciences, 26(1), 37–47.
   PubMed Web of Science ®Google Scholar
• Kasaian, J., Mosaffa, F., Behravan, J., Masullo, M., Piacente, S., Ghandadi, M., & Iranshahi, M. (2015). Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Fitoterapia, 103, 149–154.
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Consortium, O. S. D. D., & Lynn, A. (2014). g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information Modeling, 54(7), 1951–1962.
   PubMed Web of Science ®Google Scholar
• Lanktree, M. B., Haghighi, A., di Bari, I., Song, X., & Pei, Y. (2021). Insights into autosomal dominant polycystic kidney disease from genetic studies. Clinical Journal of the American Society of Nephrology, 16(5), 790–799.
   PubMed Web of Science ®Google Scholar
• Lefterova, M. I., Haakonsson, A. K., Lazar, M. A., & Mandrup, S. (2014). PPARγ and the global map of adipogenesis and beyond. Trends in Endocrinology & Metabolism, 25(6), 293–302.
   PubMed Web of Science ®Google Scholar
• Li, Q., & Shah, S. (2017). Structure-based virtual screening. In Protein bioinformatics (pp. 111–124). Springer.
   Google Scholar
• Nejabat, M., Ghodsi, R., & Hadizadeh, F. (2022). Coumarins and quinolones as effective multiple targeted agents versus Covid-19: An in silico study. Medicinal Chemistry, 18(2), 220–237.
   PubMed Web of Science ®Google Scholar
• Nejabat, M., Kalani, M. R., Nejabat, M., & Hadizadeh, F. (2022). Molecular dynamic and in vitro evaluation of chitosan/tripolyphosphate nanoparticles as an insulin delivery system at two different pH values. Journal of Biomolecular Structure Dynamics, 40(20), 10153–10161.
   PubMedGoogle Scholar
• Nejabat, M., Soltani, F., Alibolandi, M., Nejabat, M., Abnous, K., Hadizadeh, F., & Ramezani, M. (2022). Smac peptide and doxorubicin-encapsulated nanoparticles: Design, preparation, computational molecular approach and in vitro studies on cancer cells. Journal of Biomolecular Structure and Dynamics, 40(2), 807–819.
   PubMed Web of Science ®Google Scholar
• Nobakht, N., Hanna, R. M., Al-Baghdadi, M., Ameen, K. M., Arman, F., Nobahkt, E., Kamgar, M., & Rastogi, A. (2020). Advances in autosomal dominant polycystic kidney disease: A clinical review. Kidney Medicine, 2(2), 196–208. https://doi.org/10.1016/j.xkme.2019.11.009
   PubMedGoogle Scholar
• Nowak, K. L., Farmer-Bailey, H., Cadnapaphornchai, M. A., You, Z., George, D., Wang, W., Jovanovich, A., Soranno, D. E., Gitomer, B., & Chonchol, M. (2020). Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemporary Clinical Trials Communications, 19, 100635.
   PubMed Web of Science ®Google Scholar
• Parrinello, M., & Rahman, A. (1981). Polymorphic transitions in single crystals: A new molecular dynamics method. Journal of Applied Physics, 52(12), 7182–7190.
   Web of Science ®Google Scholar
• Porath, B., Gainullin, V. G., Cornec-Le Gall, E., Dillinger, E. K., Heyer, C. M., Hopp, K., Edwards, M. E., Madsen, C. D., Mauritz, S. R., & Banks, C. J. (2016). Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. The American Journal of Human Genetics, 98(6), 1193–1207.
   PubMed Web of Science ®Google Scholar
• Raphael, K., Strait, K., Stricklett, P., Baird, B., Piontek, K., Germino, G., & Kohan, D. (2009). Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. American Journal of Nephrology, 30(5), 468–473.
   PubMed Web of Science ®Google Scholar
• Rizvi, N., & Peters, S. (2017). Tolvaptan and autosomal dominant polycystic kidney disease. The New England Journal of Medicine, 377(20), 1986–1988. https://doi.org/10.1056/NEJMe1711430
   PubMed Web of Science ®Google Scholar
• Rolf, M. G., Curwen, J. O., Veldman‐Jones, M., Eberlein, C., Wang, J., Harmer, A., Hellawell, C. J., & Braddock, M. (2015). In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacology Research & Perspectives, 3(5), e00175.
   PubMed Web of Science ®Google Scholar
• Sabe, V. T., Ntombela, T., Jhamba, L. A., Maguire, G. E., Govender, T., Naicker, T., & Kruger, H. G. (2021). Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. European Journal of Medicinal Chemistry, 224, 113705.
   PubMed Web of Science ®Google Scholar
• Saini, A. K., Saini, R., & Singh, S. (2020). Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: A comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Molecular Medicine, 26(1), 1–17.
   Web of Science ®Google Scholar
• Shao, G., Zhu, S., & Yang, B. (2021). Applications of herbal medicine to treat autosomal dominant polycystic kidney disease. Frontiers in Pharmacology, 12, 629848. https://doi.org/10.3389/fphar.2021.629848
   PubMed Web of Science ®Google Scholar
• Sharma, S., Kulkarni, S. K., & Chopra, K. (2006). Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clinical and Experimental Pharmacology and Physiology, 33(10), 940–945.
   PubMed Web of Science ®Google Scholar
• Shoskes, D. A. (1998). Effect of bioflavonoids quercetin and curcumin on ischemic renal injury: A new class of renoprotective agents: 1. Transplantation, 66(2), 147–152. https://doi.org/10.1097/00007890-199807270-00001
   PubMed Web of Science ®Google Scholar
• Terker, A. S., Yang, C.-L., McCormick, J. A., Meermeier, N. P., Rogers, S. L., Grossmann, S., Trompf, K., Delpire, E., Loffing, J., & Ellison, D. H. (2014). Sympathetic stimulation of thiazide-sensitive sodium chloride cotransport in the generation of salt-sensitive hypertension. Hypertension, 64(1), 178–184.
   PubMed Web of Science ®Google Scholar
• Terker, A. S., Zhang, C., McCormick, J. A., Lazelle, R. A., Zhang, C., Meermeier, N. P., Siler, D. A., Park, H. J., Fu, Y., & Cohen, D. M. (2015). Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metabolism, 21(1), 39–50.
   PubMed Web of Science ®Google Scholar
• van de Laarschot, L. F., Te Morsche, R. H., Hoischen, A., Venselaar, H., Roelofs, H. M., Cnossen, W. R., Banales, J. M., Roepman, R., & Drenth, J. P. (2020). Novel GANAB variants associated with polycystic liver disease. Orphanet Journal of Rare Diseases, 15(1), 1–11.
   PubMed Web of Science ®Google Scholar
• Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718.
   PubMed Web of Science ®Google Scholar
• Vanommeslaeghe, K., Hatcher, E., Acharya, C., Kundu, S., Zhong, S., Shim, J., Darian, E., Guvench, O., Lopes, P., & Vorobyov, I. (2010). CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields. Journal of Computational Chemistry, 31(4), 671–690.
   PubMed Web of Science ®Google Scholar
• Viau, A., Kotsis, F., Boehlke, C., Braeg, S., Klein, M., Nitschke, R., Walz, G., & Kuehn, E. W. (2020). Divergent function of polycystin 1 and polycystin 2 in cell size regulation. Biochemical and Biophysical Research Communications, 521(2), 290–295.
   PubMed Web of Science ®Google Scholar
• Villa, F., Deak, M., Alessi, D. R., & Van Aalten, D. M. (2008). Structure of the OSR1 kinase, a hypertension drug target. Proteins: Structure, Function, and Bioinformatics, 73(4), 1082–1087.
   PubMed Web of Science ®Google Scholar
• Vitari, A. C., Deak, M., Morrice, N. A., & Alessi, D. R. (2005). The WNK1 and WNK4 protein kinases that are mutated in Gordon’s hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. The Biochemical Journal, 391(Pt 1), 17–24.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Zhao, H., Wang, Q., Zhou, X., Lu, X., Liu, T., Zhan, Y., & Li, P. (2019). Chinese herbal medicine in ameliorating diabetic kidney disease via activating autophagy. Journal of Diabetes Research, 2019, 9030893. https://doi.org/10.1155/2019/9030893
   Web of Science ®Google Scholar
• Weimbs, T., Shillingford, J. M., Torres, J., Kruger, S. L., & Bourgeois, B. C. (2018). Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clinical Kidney Journal, 11(Suppl 1), i27–i38. https://doi.org/10.1093/ckj/sfy089
   PubMedGoogle Scholar